Literature DB >> 11296138

Positron emission tomography and gallium metabolic imaging in lymphoma.

B Coiffier1.   

Abstract

Metabolic imaging allows the recognition of active tumor mass because of its fixed tracer. For patients with Hodgkin's disease and non-Hodgkin lymphoma, (67)gallium and (18)fluorodeoxyglucose (FDG) have been employed. This review describes the role of (67)gallium scintigraphy (Ga-scan) and positron emission tomography (PET) in the staging and follow-up of patients with lymphoma. These tools do not appear to be more powerful than conventional imaging for initial staging and treatment choice. Ga-scan is only valid for thoracic examination. PET imaging following treatment resolves the problem of persisting images on CT scan; nearly all patients with FDG uptake have an early relapse. Whether this examination will allow for intensified treatment and possible cure of more patients is yet to be demonstrated.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11296138     DOI： 10.1007/s11912-001-0060-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  28 in total

1.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.

Authors:  F Moog; J Kotzerke; S N Reske
Journal:  J Nucl Med       Date:  1999-09       Impact factor: 10.057

Review 2.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

3.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

Authors:  F Moog; M Bangerter; J Kotzerke; A Guhlmann; N Frickhofen; S N Reske
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease.

Authors:  M E Weinblatt; I Zanzi; A Belakhlef; B Babchyck; J Kochen
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

5.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

6.  Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.

Authors:  E Salloum; D S Brandt; V J Caride; E Cornelius; D Zelterman; W Schubert; T Mannino; D L Cooper
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

7.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.

Authors:  F Moog; M Bangerter; C G Diederichs; A Guhlmann; J Kotzerke; E Merkle; O Kolokythas; F Herrmann; S N Reske
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

8.  High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma.

Authors:  N Peylan-Ramu; T B Haddy; E Jones; K Horvath; M A Adde; I T Magrath
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

9.  Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.

Authors:  C Delcambre; O Reman; M Henry-Amar; A M Peny; M Macro; S Cheze; J Y Génot; A Tanguy; O Switsers; H L Van; J E Couëtte; M Leporrier; S Bardet
Journal:  Eur J Nucl Med       Date:  2000-02

10.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245
View more
  4 in total

1.  67Ga scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

2.  Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.

Authors:  Sith Phongkitkarun; Vithya Varavithya; Toshiki Kazama; Silvana C Faria; Martha V Mar; Donald A Podoloff; Homer A Macapinlac
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Sang Kyun Sohn; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Jae Sook Ahn; Je-Jung Lee; Hyeoung-Joon Kim; Shin-Young Jeong; Chae Moon Hong; Jung-Joon Min; Joon-Ho Moon; Deok-Hwan Yang
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 4.  Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.

Authors:  Einat Even-Sapir; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-18       Impact factor: 9.236
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.